Key takeaway
Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.
Study design
Observational meta-analysis
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
A rest-activity rhythm describes how regularly a person's activity and rest alternate across the day. The authors' background says that a disrupted rhythm is an emerging risk factor for cardiovascular disease (CVD) and death, but that the strength of the evidence was unclear. They set out to pool the available studies to assess how rhythm characteristics relate to CVD incidence or prevalence, cardiovascular mortality and all-cause mortality. They looked at three standard nonparametric measures: interdaily stability (how stable the rhythm is from one day to the next), intradaily variability (how fragmented it is) and relative amplitude (how robust or strong it is).
Who and how
This was a systematic review and meta-analysis of cohort or cross-sectional studies. The authors searched PubMed, Web of Science, the Cochrane Library and Embase for studies published up to August 2025 and included 7 studies with 109,365 participants. The exposures were the three nonparametric rest-activity rhythm parameters: interdaily stability, intradaily variability and relative amplitude. The abstract does not report the countries, ages, how the rhythm was recorded (device or number of days worn) or the follow-up lengths of the included studies; full details are not in the abstract.
The primary outcomes were cardiovascular mortality and all-cause mortality, and the secondary outcomes were CVD prevalence and incidence. The pooled results are hazard ratios for mortality and an odds ratio for CVD prevalence, each with a 95% confidence interval. The abstract does not state how many studies contributed to each analysis, the pooling model, the heterogeneity, the adjustments made in the original studies, or whether each ratio applies per unit, per standard deviation or by category of the measure.
What it found
- 1A weaker contrast between active and rest periods went with higher mortality: lower relative amplitude was associated with higher cardiovascular mortality (HR 1.50, 95% CI 1.13 to 1.98) and higher all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68).
- 2A more fragmented rhythm went with a small rise in all-cause mortality: higher intradaily variability was associated with an HR of 1.05 (95% CI 1.02 to 1.09).
- 3Higher intradaily variability was also associated with more cardiovascular disease when the rhythm was measured, with an odds ratio of 1.73 (95% CI 1.21 to 2.47) for CVD prevalence; a prevalence comparison cannot show which came first.
- 4How similar the rhythm is from one day to the next did not matter in these data: interdaily stability showed no significant association with any outcome. The abstract does not report results for CVD incidence.
Limits & uncertainty
- 1The authors point to a gap in the evidence: future work should investigate whether appropriately timed physical activity and sleep, or other interventions targeting the rhythm, can mitigate cardiovascular risk. Nothing here shows that changing the rhythm changes risk.
- 2Our observation: only seven studies were pooled, and the abstract does not say how many fed each estimate, so some of the ratios may rest on very few studies.
- 3Our observation: all the data are observational. Illness can itself disturb the rhythm, so the CVD prevalence association (odds ratio 1.73) may run in either direction, and the abstract does not say what the included studies adjusted for.
- 4Our observation: these measures come from activity recordings processed by research algorithms, and the abstract does not say which devices or how many days of wear were used, so the ratios may not carry over to the scores on a consumer wearable. This reading rests on the abstract alone.
What to take from it
The studies pooled here found that people with weaker or more fragmented daily rhythms had higher mortality, with relative amplitude showing the clearest link. A pattern with clearly active days and consolidated rest fits a stronger rhythm, but the evidence does not show that changing your pattern lowers risk; the authors themselves say that remains to be tested.
A rhythm number from a device is not a risk score, a diagnosis or a sign of heart disease, and anyone worried about heart symptoms or sleep should talk to a clinician. Confidence is low to moderate: the associations are consistent in direction for some measures, but they come from a small number of observational studies.
Reading your own data
Look at your sleep and daytime activity together in your device's trend view: regular bed and wake times, a clear activity peak in the daytime and little movement at night, compared week to week on the same device. The research measures (interdaily stability, intradaily variability, relative amplitude) are calculated from activity recordings by specific algorithms, so a consumer regularity or consistency score is not automatically equivalent. Shift work, travel, illness and days when you did not wear the device all disturb the rhythm, so mark them in your log before you read a trend.
How to read this evidence
Pooling observational studies does not remove their confounding. Check overlapping cohorts and whether relative effects are being confused with absolute benefits.
Sources & attribution
Association Between Rest-Activity Rhythm and Cardiovascular Disease, Cardiovascular Mortality, and All-Cause Mortality: A Systematic Review and Meta-Analysis
Journal of the American Heart Association · 2026-10-06
DOI: 10.1161/JAHA.125.048656 ↗PubMed · 42757889 ↗MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Five exercise types lowered resting blood pressure, isometric training the most
Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.
British Journal of Sports Medicine
A salt substitute lowered stroke, major cardiovascular events and death in rural China
In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.
The New England Journal of Medicine
Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation
Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.
The New England Journal of Medicine
Evolocumab added to statins lowered LDL by 59% and reduced cardiovascular events
In 27,564 people with atherosclerotic cardiovascular disease already on a statin, adding evolocumab lowered LDL cholesterol by 59% versus placebo at 48 weeks and reduced the primary composite of cardiovascular events to 9.8% from 11.3% over a median 2.2 years (HR 0.85, 95% CI 0.79 to 0.92). Amgen funded the trial, follow-up was short, and only people with established disease took part, so the result does not speak to healthy people or to long-term safety.
The New England Journal of Medicine

